Adial Pharmaceuticals (NASDAQ:ADIL) Trading Down 1.6% – Should You Sell?

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) traded down 1.6% during mid-day trading on Tuesday . The company traded as low as $0.35 and last traded at $0.36. 405,790 shares were traded during trading, a decline of 47% from the average session volume of 759,685 shares. The stock had previously closed at $0.36.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. Zacks Research cut shares of Adial Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 20th. Maxim Group upgraded shares of Adial Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.50 price objective for the company in a report on Tuesday, September 30th. Weiss Ratings restated a “sell (e+)” rating on shares of Adial Pharmaceuticals in a report on Wednesday, October 8th. Finally, Wall Street Zen upgraded shares of Adial Pharmaceuticals to a “sell” rating in a report on Saturday, July 26th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $4.75.

Adial Pharmaceuticals Stock Down 1.6%

The company has a market cap of $7.80 million, a price-to-earnings ratio of -0.34 and a beta of 1.36. The company’s fifty day moving average price is $0.37 and its two-hundred day moving average price is $0.48.

Adial Pharmaceuticals (NASDAQ:ADIL) last released its quarterly earnings results on Wednesday, August 13th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.04. On average, equities research analysts predict that Adial Pharmaceuticals, Inc. will post -1.53 earnings per share for the current fiscal year.

About Adial Pharmaceuticals

Adial Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.